Drug Product, Drug Substance, Stability Services

Features

Agilent stability protocols are designed to support global registration of your drug product. These protocols include:
Stability programs to support APIs and the final drug product
Qualified stability chambers for all ICH conditions, including photostability
GLP studies with dose formulation analysis
Statistical analysis and data trending

News

Colorado Governor Polis Helps Agilent Break Ground on $725 Million Expansion of Manufacturing Operations in Frederick

Agilent leaders joined Colorado Governor Jared Polis and local government officials to break ground on $725 million investment to double manufacturing capacity of therapeutic nucleic acids in Frederick, Colorado. The investment will create more than 160 life science jobs in the area. Agilent’s manufacturing facilities in Colorado produce siRNA, antisense molecules, and CRISPR guide RNA molecules.

16 Feb 2023

Agilent Investing $725 Million to Expand State-of-the-Art Manufacturing Capacity for Production of Nucleic Acid-Based Therapeutics

Investment will double capacity to produce active pharmaceutical ingredients used in therapeutics for a broad range of diseases. The addition of two new manufacturing lines (known as Trains C and D) will enable Agilent to meet growing demand for siRNA, antisense and CRISPR guide RNA molecules. Agilent expects customer shipments from the expansion to begin in 2026.

05 Dec 2022

Videos

Literature

Brochures

Accelerate Your Journey from Clinic to Market

Produce high-quality oligo APIs and efficiently advance from clinic to market, delivering therapeutics to patients with unmet medical needs

Brochures
English
24 Oct 2023
3.19 MB
PDF